H.C. Wainwright raised the firm’s price target on Cosmo Pharmaceuticals (CMOPF) to CHF 160 from CHF 130 and keeps a Buy rating on the shares. The firm cites the addition of the intrinsic value of Breezula to its valuation assessment for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMOPF:
- Cosmo’s Clascoterone Delivers Strong 12‑Month Data in Male Hair Loss, Paving Way for 2027 Filings
- Cosmo Shareholders Approve All AGM Resolutions and EUR 2.10 Dividend
- Cosmo to Showcase Real-Time Medical AI Platforms at NVIDIA GTC 2026
- Cosmo Sets April General Meeting with Name Change and Payout on Agenda
- Cosmo Pharmaceuticals Lifts Recurring Revenues, Boosts Dividend and Sets Growth Path to 2030